Approval of audited consolidated and standalone financial results and recommendation of dividend
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Windlas Biotech reported FY2026 consolidated revenue of Rs. 9,040.89 million, up 19% from Rs. 7,598.78 million in FY2025. Profit after tax grew to Rs. 664.56 million from Rs. 609.94 million, an increase of approximately 9%. EPS stood at Rs. 31.60 versus Rs. 29.19 in the prior year. The Board recommended a dividend of Rs. 6.30 per share (126% on face value of Rs. 5). During the year, the company completed a Rs. 470 million buyback of 470,000 shares at Rs. 1,000 per share and dissolved its US subsidiary Windlas Inc. USA. ESOP expenses increased significantly to Rs. 166.11 million from Rs. 24.60 million. Statutory auditors J C Bhalla & Co issued an unmodified (clean) opinion on both standalone and consolidated financial results.
The company delivered solid revenue growth near 20% with PAT growth of ~9%, suggesting healthy operational performance. The 126% dividend payout signals confidence in cash flows. However, EBITDA margins compressed year-over-year, which investors should monitor. The clean audit opinion removes any immediate concerns about financial reporting quality.